5 completed, 3 terminated. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 3 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
Follow mecasermin: new trials by email Literature Review of mecasermin trials Research Report on mecasermin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency Increlex - Short Stature | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 7 | 2015-12-21 | 2024-02-28 |
| Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack mecasermin, 0.9% sodium chloride injection - Heart Failure, Myocardial Infarction | Phase 1 / Phase 2 | Completed | University College Cork | 47 | 2011-10-01 | 2017-03-30 |
| Effects of IGF-I in HIV Metabolic Disease mecasermin, Placebo control - HIV Lipodystrophy | Phase 1 | Terminated | University of Texas Southwestern Medical Center | 16 | 2011-06-01 | 2016-03-23 |
| Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) rhIGF-1 - Rett Syndrome | Phase 1 | Completed | Boston Children's Hospital | 12 | 2010-12-01 | 2017-06-22 |
| Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy IGF-1 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 44 | 2010-11-01 | 2021-01-20 |
| IGF-1 Therapy in Patients With Cystic Fibrosis recombinant human IGF-1, Placebo - Cystic Fibrosis | Phase 1 | Terminated | Stony Brook University | 15 | 2008-06-01 | 2013-01-28 |
| Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Increlex - Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID) | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 6 | 2007-06-01 | 2015-07-03 |
| Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents RhIGF-1 - Anorexia Nervosa | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 16 | 2007-03-01 | 2021-11-18 |
Anorexia Nervosa (1) · Body Weight (1) · Cystic Fibrosis (1) · Dwarfism (1) · Failure to Thrive (1) · Heart Failure (1) · Muscular Dystrophy, Duchenne (1) · Myocardial Infarction (1) · Rett Syndrome (1) · X-Linked Combined Immunodeficiency Diseases (1)
Children's Hospital Medical Center, Cincinnati (2) · Boston Children's Hospital (1) · Massachusetts General Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Stony Brook University (1) · University College Cork (1) · University of Texas Southwestern Medical Center (1)
United States (6) · Ireland (1) · Netherlands (1)
Gajanathan Muthuvel, MD (1) · Madhu Misra (1) · Meilan Rutter, MD (1) · Mustafa Sahin, MD, PhD (1) · Noel Caplice, MB, PhD (1) · Philippe Backeljauw, MD (1) · Roy J Kim, MD, MPH (1) · Suk S De Ravin, M.D. (1) · Thomas A Wilson, MD (1)